DBV Technologies shares, among the biggest decliners in the SBF 120, fall 2.5%
The Châtillon-based biotech is retreating mid-session, in an almost unchanged SBF 120, after several weeks of rebound. This decline comes as new clinical data on its patch against peanut allergy have just been presented in the United States.
A pullback that slows a nearly 20% weekly rebound
The stock loses 2.26% to €2.07 intraday, while the SBF 120 remains stable. This decline follows a 19.56% weekly rebound, which had brought the price back near the €2.13 resistance level.
The move is part of a setup still marked by a significant gap with the MM200, located at €2.83, nearly 27% above the current price.
The RSI at 61 reflects the magnitude of the recent recovery. However, the stock remains above its MM20 (€1.83) and MM50 (€1.92), signalling that the rebound is not erased. It also shows a 15.08% decline over three months, a drop that the recent sessions' rise has only partially reduced.
Analyses from the VITESSE study at the ACAAI congress, and a regulatory file under review
Three additional analyses of the phase 3 VITESSE study were presented at the American College of Allergy, Asthma & Immunology congress in Phoenix. They concern the severity of allergic reactions, immunological biomarkers and the daily use of the patch Viaskin Peanut in children aged 4 to 7.
The trial, conducted on 654 children over 12 months, had met its primary endpoint with 46.6% responders under treatment, versus 14.8% under placebo.
The patch's marketing authorization application is under review by the FDA, which is expected to decide in the fourth quarter of 2026 whether the accelerated procedure is granted, according to the information published with the nine-month 2026 results (October 28, 2026). These accounts also flagged doubt about the going concern and a funding requirement beyond the third quarter of 2027.
On positioning, four funds together hold 2.89% of the capital sold short according to the declarations consulted, down 0.26 points over thirty days, indicating a bearish bet that is loosening slightly without disappearing.
